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expression of CD79b (in 94.2% of cells). The same phenotype was
registered in one patient with del(6q23), comprising CD78b+ (in
97.8% of cells), CD22+ (in 62.6% of cells) and CD38+ (in 32.5% of
cells). In 2 patients (6%) with del (11)(q23) expression of CD79b
(in 47.3–44.8% of cells) and CD38 (in 35.3–64.4% of cells).
Conclusion: Expression of CD79b, CD22, CD38 is the main fea-
ture of cells with recurrent genetic injuries. Immunophenotype
without expression of CD79b, CD22, CD38 in most cases differen-
tiates CLL patients with del(13)(q14.3), del (13)(q34), (13q)(34)
trisomy and with normal karyotype. Coexpression in the most
of the cells of the three antigens CD79b, CD22, CD38 and more
bright expression of CD20 proposes trisomy 12 or del(6q). Partial
expression of CD79b and CD38 may correlate with del(11)(q23).
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Breast cancer is one of the most common cancers in women.
The incidence of breast cancer in 2014 in the Republic of Mordovia
was 69.9 per 100,000 female populations. Breast cancer occurs
when excessive expression of oncoproteins switches in the case
of transformation of proto-oncogene in PRADI. In primary breast
tumors, mutations and the expression of the three oncogenes
Her2/neu, C-mys, Int-2, as well as in supressonyh genes – the
p53 gene and the retinoblastoma gene RB are the most common.
Several studies found that oncogene – C-mys was expressed in
16.8% of primary breast cancer cases and in 35% cases with sub-
sequent development of metastases. Proteins that stimulate the
phosphorylation of mitogen-activated protein kinasescan activa-
teunder the influence of growth factors. Development of breast
cancer is regulated by a complex interaction of many hormones
and growth factors. Currently, one of the leading theories of
developing breast cancer is the increased hormonal stimulation
of proliferative processes in the development of neoplasia. One
of the manifestations of hormonal imbalance in tumor during a
regular decrease in blood competitive inhibitor of the biological
effects of estrogen – progesterone, which is in correlation with
the stage of the spread of neoplasia. The role of the overproduc-
tion of estrogen in the pathogenesis of breast cancer is confirmed
by the fact that in women who underwent oophorectomy before
the age of 38 years, the risk of breast cancer development is 1.5
times less than in those who did not have such operation. Exces-
sive accumulation of lipid peroxidation products in the area of
neoplasia activates mechanisms violation of intercellular interac-
tion that caused the destruction of the lipid components of
membranes.
The study group included 112 patients treated at the State
Institution of Health of the Republic of Mordovia ‘‘National
Oncology Center”. To identify the nature of tumors, all patients
underwent immunohistochemical analysis. Androgen receptors
were found in 48% of breast cancer cases, the expression level
of androgen receptor in the tumor was much lower than the
expression level of estrogen and progesterone receptors. Low
levels of progesterone receptor expression in breast cancer cells
were combined with high levels of expression of Ki-67 antigen,
HER-2 oncoprotein in tumor cells. Patients with HER-2 (3+) and
(2+) had more frequent multiple metastases in lymph nodes com-
pared to patients with HER-2 (0) and (1+) phenotypes. Maximum
expression of HER-2 oncoprotein in tumor cells indicated high
metastatic potential and poor prognosis.
It may be concluded that the cellular and molecular mecha-
nisms of breast cancer are complex. Therefore, carcinogenesis
has a ‘‘multistep” nature and at least two or more mutations in
the cells of the same clone – parent and child are required to gen-
erate malignant tumors. Thus, the development of oncogenic
transformation does not necessarily mean the process of tumor
formation.
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Background: Identification of DNA-based biomarkers of cancer
cells is highly promising and rapidly developing direction that can
advance early detection and therapy of malignancies. DNA
adducts are felicitous markers of cancer, because their chemical
structure is significantly different from that of mutated or methy-
lated DNA, that allows to determine them with high precision
using mass spectrometry. The aim of this work is to develop the
methodology of sample preparation and its mass spectrometric
analysis. Samples were prepared from the blood plasma and from
the tumor tissue from lung cancer patients and from blood of
healthy individuals.
Materials and methods: DNA was isolated from the blood
plasma and tissue by using column method (BioSilica, Russia)
The final yield from 1 ml of blood was 100 ng. DNA samples were
subjected to acid hydrolysis (1 M HCl) at 70 C. After 3 h, the
hydrolysis was stopped by cooling on ice for 5 min and later on
adding an equivalent amount of an alkali and a phosphate buffer
solution (pH 7). To assess the extent of hydrolysis of the samples
they were analysed by electrophoresis on a 1.2% agarose gel in
Tris-acetate buffer. The samples were extracted at cartridge HF
Bond Elut-C18 100 mg, 1 ml (Agilent Technologies, USA) and
eluted in several fractions with a gradual increase of methanol
in the eluent. Stream of nitrogen was applied to dry the extract.
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The samples were subjected to mass spectrometric analysis after
pre-separation by UHLC Ultimate 3000 RS (Dionex, USA) in a col-
umn Dionex Acclaim RSLC 120 C18 (2.1  50 mm 120 A, 0.2 lm)
flow rate of 0.5 ml/min using as eluents 0.1% solution of formic
acid in water (A) and 0.1% solution of formic acid in atsetontrile
(B). Elution was carried out in gradient mode: (%B): 0–3min (5%),
3–28min (5–95%), 28–30 min (95%), 30–31 min (95–5%), 31–35 min
(5%). Mass spectrometry was carried out on ESI-qTOF ultrahigh
resolution Maxis 4G (Bruker, Germany) in the positive ion detec-
tion mode range 50–1000 m/z, 2 Hz with the following settings
electrospray ion source: CV 3800 V, Nebulizer gas 1 bar, Dry Gas
8 l/min, Dry Temp: 200 C.
Results: It was found that the DNA which was cleaved with
acid hydrolysis in the result contained single DNA bases. The
samples were stable at 4 C for at least 7 days. The optimal eluent
for solid phase extraction of DNA is 80% solution of methanol in
water. The number of DNA adducts was evaluated by the inte-
grated value of the mass spectrometric response detector. It
was shown that most amount of adducts 4-hydroxy-1-(3-
pyridyl)-1- butanone and N3-(2-carbamoyl-2-hydroxyethyl)ade
nine was found in DNA samples derived from tumor tissue. The
adduct N7-(2-carbamoyl-2-hydroxyethyl)guanine was found in
tumor tissue samples and DNA derived from plasma, as well as
in all samples of healthy tissue.
Conclusion: The established protocol of DNA sample prepara-
tion followed by analysis using a mass spectrometer high resolu-
tion allows to detect the content of the DNA adducts in small DNA
probes (100 ng). We found, that acid hydrolysis is cheaper and
more practical in comparison to enzymatic digestion in order to
generated samples containing single DNA bases without damag-
ing the structure of adducts.
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Mutations in BRCA1 and CHEK2 genes associated with
hereditary breast cancer were tested in 7920 randomly selected
individuals of Novosibirsk (Russia). Mutations BRCA1 5382insC
and CHEK2 1100delC were the most frequent, they were found
in 0.25% and 0.4% of the general population respectively. We
suggested to find mutations carriers by the screening of all
breast/ovary cancer patients for the most frequent mutations
(BRCA1 5382insC and CHEK2 1100delC) with subsequent analysis
of the first-line relatives of cancer patients if one of the mutations
was found.
From June 2013 till January 2015, all patients from Novosibirsk
regional oncology hospital with the diagnosis of breast cancer
and some patients with the diagnosis of ovary cancer were tested
for mutations BRCA1 5382insC and CHEK2 1100delC. A total of
2655 cancer patients were analyzed independently of their family
history. We found 122 mutations carriers, among them 99
patients with mutations in BRCA1 gene and 23 patients with
mutation CHEK2 1100delC. Among mutation carriers, 105 patients
agreed to have a medical genetic counseling and after pedigree
analysis 193 first-line relatives aged above 25 years were eluci-
dated. One hundred ten first-line relatives of mutation carriers
were analyzed for the mutations presence and 40 mutations car-
riers were found among relatives.
From September 2013 till December 2013, 32 relatives of BRCA
mutation carriers underwent breast MRI. In 5 cases, breast can-
cer was detected by MRI and all cancers except one were con-
firmed histologically with biopsy analysis. Importantly, all
tumors were 5 mm and less in size, stage I cancer was detected
in all cases.
At a follow-up of 1.5 years, all 105 mutation carrier probands
were interviewed by phone regarding possible relapse and/or
possible primary cancer in their relatives. Five of 105 probands
lost to follow-up may have died. Among responding 100 patients,
2 died as reported by relatives, relapse was reported in 7 probands
– mutation carrier probands, primary tumors were reported in 8
relatives of probands.
Mutation carrier probands reported one bilateral breast
cancer, four ovary cancers, one bladder cancer and one non-
specified oncogynecological tumor.
There were five cases of primary breast cancer, one ovary can-
cer, one colon cancer, one lung cancer among relatives of breast
cancer patients with mutations. The frequency of tumors found
in mutation carriers exceeded the average frequencies of cancer
for this population.
The economic value of the regional genetic screening can be
easily estimated according to the data obtained in this study
and data on treatment cost for stage I and stage IV breast cancer.
To summarize briefly, the screening of hot-spot mutations
provides not only increase of lifespan expectancy and life quality
for mutation carriers, but can be also a tool for financial saving of
medical system due to the increase of early stage breast cancer
detection.
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